Venetoclax D8
- CAS No.
- 1257051-06-1
- Chemical Name:
- Venetoclax D8
- Synonyms
- VENETOCLAX-D8;D8-Venetoclax;Venetoclax D8;Venetoclax-D8 (Standard);Venetoclax-d8 (piperazine-d8);Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl-2,2,3,3,5,5,6,6-d8]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-;Venetoclax-d8: 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl-2,2,3,3,5,5,6,6-d8)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide
- CBNumber:
- CB73339265
- Molecular Formula:
- C45H42ClD8N7O7S
- Molecular Weight:
- 876.49
- MDL Number:
- MOL File:
- 1257051-06-1.mol
- MSDS File:
- SDS
Venetoclax D8 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0103326 | Venetoclax-d8 99.76% | 1257051-06-1 | 1mg | $422 | 2026-06-04 | Buy |
| ChemScene | CS-0103326 | Venetoclax-d8 99.76% | 1257051-06-1 | 5mg | $1062 | 2026-06-04 | Buy |
| ChemScene | CS-0103326 | Venetoclax-d8 99.76% | 1257051-06-1 | 10mg | $1690 | 2026-06-04 | Buy |
| ChemScene | CS-0103326 | Venetoclax-d8 99.76% | 1257051-06-1 | 25mg | $3380 | 2026-06-04 | Buy |
| ChemScene | CS-0103326 | Venetoclax-d8 99.76% | 1257051-06-1 | 50mg | $5406 | 2026-06-04 | Buy |
Venetoclax D8 Chemical Properties, Uses, Production
Uses
Venetoclax-d8 is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].
References
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. DOI:10.1038/nm.3048
[3] Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47. DOI:10.1182/blood-2014-05-574566
[4] Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102(4):755-764. DOI:10.3324/haematol.2016.159160
Venetoclax D8 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Champ Biopharmaceuticals Co., Ltd. | 021-61537865 13585780846 | sales@champchem.com | China | 442 | 58 |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Quality Control Solutions Ltd. | 0755-66853366 13670046396 | orders@qcsrm.com | China | 18188 | 56 |
| Artis Biotech Co. Ltd. | 18108108965 18108108965 | sales@artisbio.com | China | 2503 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Hubei Yangxin Medical Technology Co., Ltd. | 15374522761 | 3003392093@yongstandards.com | China | 9995 | 55 |
| Nanjing Haolv Biotechnology Co.,Ltd | 025-84622273 17361806303 | kexin.zhou@haolvbiotech.com | China | 3009 | 58 |
| Zhengzhou Acme Chemical Co., Ltd. | 037163312495 13303845143 | 1416159398@qq.com | China | 10150 | 58 |
| Jinan blalong chemical co. LTD | 2710913286@qq.com | 1513643261@qq.com | China | 14227 | 58 |
| Changzhou Xianglong Pharmaceutical Technology Co., LTD | 18661161657 | sales@xianglongpharm.com | China | 9998 | 58 |
View Latest Price from Venetoclax D8 manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Venetoclax-D8
1257051-06-1
|
$322.00 | 99.47% | 10g | TargetMol Chemicals Inc. |
-
- Venetoclax-D8
1257051-06-1
- $322.00
- 99.47%
- TargetMol Chemicals Inc.
